TransMedics Group, Inc. (NASDAQ:TMDX) Receives $122.70 Consensus PT from Analysts

TransMedics Group, Inc. (NASDAQ:TMDX) has been assigned an average rating of “Moderate Buy” from the eleven brokerages that are presently covering the firm, MarketBeat reports. Three research analysts have rated the stock with a hold recommendation, seven have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $122.70.

TMDX has been the subject of a number of research reports. Robert W. Baird decreased their target price on TransMedics Group from $150.00 to $120.00 and set an “outperform” rating for the company in a report on Wednesday, December 11th. Piper Sandler decreased their price objective on shares of TransMedics Group from $110.00 to $90.00 and set an “overweight” rating for the company in a research note on Wednesday, December 11th. Needham & Company LLC reissued a “hold” rating on shares of TransMedics Group in a report on Wednesday, December 11th. Baird R W raised TransMedics Group to a “strong-buy” rating in a report on Tuesday, September 24th. Finally, JPMorgan Chase & Co. reiterated a “neutral” rating and set a $75.00 price target (down from $116.00) on shares of TransMedics Group in a research report on Tuesday, December 17th.

TransMedics Group Stock Performance

Shares of TransMedics Group stock opened at $57.20 on Friday. The company has a 50 day moving average price of $71.50 and a 200 day moving average price of $117.66. The firm has a market capitalization of $1.92 billion, a P/E ratio of 60.85 and a beta of 2.12. The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42. TransMedics Group has a 52 week low of $56.03 and a 52 week high of $177.37.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings data on Monday, October 28th. The company reported $0.12 earnings per share for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17). The company had revenue of $108.76 million for the quarter, compared to analysts’ expectations of $115.00 million. TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. TransMedics Group’s quarterly revenue was up 63.7% compared to the same quarter last year. During the same period last year, the firm earned ($0.12) earnings per share. Sell-side analysts expect that TransMedics Group will post 1 EPS for the current year.

Insiders Place Their Bets

In other TransMedics Group news, Director Edward M. Basile sold 6,750 shares of the company’s stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $83.55, for a total transaction of $563,962.50. Following the completion of the transaction, the director now directly owns 732 shares in the company, valued at approximately $61,158.60. This represents a 90.22 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Tamer I. Khayal sold 1,084 shares of the stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $86.40, for a total transaction of $93,657.60. Following the transaction, the insider now directly owns 20,843 shares in the company, valued at approximately $1,800,835.20. The trade was a 4.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.00% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On TransMedics Group

Several large investors have recently bought and sold shares of TMDX. USA Financial Formulas purchased a new position in shares of TransMedics Group in the third quarter valued at approximately $55,000. Quarry LP lifted its holdings in TransMedics Group by 557.1% in the 3rd quarter. Quarry LP now owns 368 shares of the company’s stock valued at $58,000 after purchasing an additional 312 shares in the last quarter. National Bank of Canada FI lifted its holdings in TransMedics Group by 174.7% in the 3rd quarter. National Bank of Canada FI now owns 412 shares of the company’s stock valued at $65,000 after purchasing an additional 262 shares in the last quarter. Farther Finance Advisors LLC boosted its stake in TransMedics Group by 187.0% during the 3rd quarter. Farther Finance Advisors LLC now owns 485 shares of the company’s stock worth $76,000 after purchasing an additional 316 shares during the last quarter. Finally, Rakuten Securities Inc. purchased a new stake in shares of TransMedics Group during the third quarter worth $126,000. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.